Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Reporting Period: Quarter and nine months ended September 30, 2025
Operations: A Nevada holding company with operations conducted entirely in the People's Republic of China (PRC) through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. The company develops, manufactures, and markets pharmaceutical products (injectables, tablets, capsules) and healthcare products (masks, sanitizers).
Capital Structure: 5,022,002 shares of common stock outstanding as of November 10, 2025. A 1-for-10 reverse stock split was implemented on April 15, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $756,217 | $1,100,152 | $2,918,271 | $3,394,934 |
| Cost of Revenue | $815,871 | $1,619,801 | $3,200,996 | $5,219,993 |
| Gross Loss | $(59,654) | $(519,649) | $(282,725) | $(1,825,059) |
| Net Loss | $(651,482) | $(1,117,911) | $(1,965,421) | $(3,511,933) |
| Loss Per Share (Basic/Diluted) | $(0.17) | $(0.65) | $(0.57) | $(2.25) |
| Cash and Equivalents (End of Period) | $267,625 | $718,691 | $267,625 | $718,691 |
| Total Assets | $15,804,793 | $14,887,524 | $15,804,793 | $14,887,524 |
| Total Liabilities | $7,490,796 | $7,139,620 | $7,490,796 | $7,139,620 |
| Stockholders' Equity | $8,313,997 | $7,747,904 | $8,313,997 | $7,747,904 |
Liquidity & Debt: Current liabilities ($6.62M) exceed current assets ($2.33M) by approximately $4.3 million. The company holds lines of credit totaling approximately $1.96M (current portion) and owes $1.41M to related parties (Chairperson Li).
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 31% in Q3 2025 and 14% YTD 2025 compared to 2024. The decline is attributed to competitors passing generic drug consistency evaluations and entering Centralized Procurement (CP), while CPHI's peer products have not yet qualified, leading to reduced sales.
- Improved Gross Loss: Gross loss margin improved significantly (from 47.2% to 7.9% in Q3; from 53.8% to 9.7% YTD). This was driven by lower depreciation (certain PP&E fully depreciated) and reduced inventory obsolescence charges.
- Accounts Receivable Write-off: In August 2025, the company wrote off $13.7 million of accounts receivable aged over eight years. This reduced the allowance for credit losses from $13.59M (Dec 2024) to $0.07M (Sep 2025), significantly improving the balance sheet presentation of receivables.
- Intangible Asset Acquisition: In August 2025, the company issued 1.76 million shares (valued at $2.45M) to acquire a patent for Apremilast (treatment for COPD) via the "Yan Yang Agreement."
- Operating Expenses: General and administrative expenses increased YTD due to higher amortization of intangible assets, while R&D expenses decreased.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has disclosed substantial doubt about the company's ability to continue as a going concern within one year. This is due to an accumulated deficit of $46.0 million, recurring net losses, and a working capital deficit. Mitigation plans include enhancing advance payment sales models, strengthening collections, and exploring strategic alternatives for nutrition products.
- Regulatory Environment: The company faces challenges with China's Centralized Procurement (CP) policies, which drastically reduce drug prices. CPHI is balancing the investment required for consistency evaluations against the risk of price erosion.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness regarding a lack of accounting personnel knowledgeable in U.S. GAAP.
- Capital Constraints: Cash on hand is limited ($0.27M). The company relies on advances from the Chairperson ($1.41M total) and bank lines of credit. There is no assurance that additional financing will be available.
- Dividend Restrictions: PRC laws restrict the remittance of funds from the subsidiary to the parent company. Statutory surplus reserve requirements exceed the subsidiary's net assets, preventing dividend distributions.
Investor Verification Checklist
- Going Concern Status: Verify the feasibility of management's plans to secure working capital and whether the Chairperson will continue to provide personal advances.
- Revenue Sustainability: Assess the timeline for CPHI's products to pass consistency evaluations and qualify for Centralized Procurement to reverse revenue declines.
- Internal Control Remediation: Confirm if the company has hired U.S. GAAP-compliant accounting personnel to address the material weakness in internal controls.
- Debt Maturity: Review the maturity dates of the $1.96M current lines of credit and the $1.41M related party borrowings to assess immediate refinancing needs.
- Intangible Asset Valuation: Evaluate the commercial viability and amortization schedule of the newly acquired Apremilast patent ($2.45M cost).